{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [43, 58]}, {"key": "the-target", "type": "clause", "offset": [59, 69]}, {"key": "the-applicable", "type": "clause", "offset": [91, 105]}, {"key": "accepted-cell-line", "type": "definition", "offset": [106, 124]}, {"key": "the-criteria", "type": "clause", "offset": [455, 467]}, {"key": "parent-compound", "type": "definition", "offset": [498, 513]}, {"key": "provided-that", "type": "clause", "offset": [517, 530]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [558, 576]}, {"key": "based-on", "type": "definition", "offset": [613, 621]}, {"key": "relating-to", "type": "definition", "offset": [634, 645]}, {"key": "the-parent", "type": "clause", "offset": [646, 656]}, {"key": "related-to", "type": "clause", "offset": [770, 780]}, {"key": "the-activity", "type": "clause", "offset": [781, 793]}, {"key": "the-understanding", "type": "clause", "offset": [824, 841]}], "size": 5, "samples": [{"hash": "a7GMUGHV4UN", "uri": "/contracts/a7GMUGHV4UN#candidate-compound", "label": "Cell Line Collaboration and License Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}, {"hash": "6HTQseXwE8e", "uri": "/contracts/6HTQseXwE8e#candidate-compound", "label": "Extended Collaboration and License Agreement (BTHC VI Inc)", "score": 21.0, "published": true}, {"hash": "5u4GMfmN1Md", "uri": "/contracts/5u4GMfmN1Md#candidate-compound", "label": "Extended Collaboration and License Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}], "snippet": "means:\n(a) any compound that has activity, with respect to the target protein expressed by the applicable Accepted Cell Line, which activity is initially discovered or detected by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line, where such activity is potentially useful for therapeutic or prophylactic use, or\n(b) any compound that is an analog, homolog, isomer or other chemical derivative of a compound that meets the criteria in subsection (a) above (the \u201cParent Compound\u201d), provided that such compound (i) was made by or on behalf of BMS or its Affiliate or sublicensee based on information relating to the Parent Compound, and (ii) has activity that is potentially useful for therapeutic or prophylactic use and is similar or related to the activity of such Parent Compound (with the understanding that such activity may be superior to the activity of the Parent Compound, in any appropriate criteria).", "hash": "669ae54462668ba66ab36dd38387bb0a", "id": 1}, {"snippet_links": [{"key": "lead-compound", "type": "definition", "offset": [8, 21]}, {"key": "the-jrc", "type": "clause", "offset": [28, 35]}, {"key": "clinical-development", "type": "definition", "offset": [63, 83]}], "size": 3, "samples": [{"hash": "kLQKX8KPOQu", "uri": "/contracts/kLQKX8KPOQu#candidate-compound", "label": "Research and License Agreement (Icagen Inc)", "score": 19.0, "published": true}, {"hash": "3PgfDn4NlW4", "uri": "/contracts/3PgfDn4NlW4#candidate-compound", "label": "Research and License Agreement (Icagen Inc)", "score": 19.0, "published": true}, {"hash": "1YfDNhDwUr9", "uri": "/contracts/1YfDNhDwUr9#candidate-compound", "label": "Research and License Agreement (Icagen Inc)", "score": 19.0, "published": true}], "snippet": "means a Lead Compound which the JRC has proposed to Abbott for clinical development in humans, or a salt, ester, amide, complex, chelate, hydrate, stereoisomer, crystalline or amorphous form, prodrug, metabolite, or metabolic precursor of such Lead Compound.", "hash": "5500da06b585d5a56ca83a5f149b4f5e", "id": 2}, {"snippet_links": [{"key": "the-joint-steering-committee", "type": "clause", "offset": [29, 57]}, {"key": "this-agreement", "type": "clause", "offset": [64, 78]}, {"key": "screening-activities", "type": "definition", "offset": [93, 113]}, {"key": "if-applicable", "type": "clause", "offset": [119, 132]}, {"key": "feasibility-study", "type": "definition", "offset": [139, 156]}, {"key": "development-of-a", "type": "clause", "offset": [174, 190]}], "size": 3, "samples": [{"hash": "g1EGTu8IJWu", "uri": "/contracts/g1EGTu8IJWu#candidate-compound", "label": "Technology License, Development, Research and Collaboration Agreement (Amyris, Inc.)", "score": 21.7173175812, "published": true}, {"hash": "gOrwnIYtIRd", "uri": "/contracts/gOrwnIYtIRd#candidate-compound", "label": "Technology License, Development, Research and Collaboration Agreement (Amyris, Inc.)", "score": 21.6625595093, "published": true}, {"hash": "f0jQMbI8zEb", "uri": "/contracts/f0jQMbI8zEb#candidate-compound", "label": "Technology License, Development, Research and Collaboration Agreement (Amyris, Inc.)", "score": 21.4873371124, "published": true}], "snippet": "means a Compound selected by the Joint Steering Committee under this Agreement, for study in Screening Activities and, if applicable, in a Feasibility Study, directed toward development of a Product.", "hash": "6d439b3af7392779f1be9d4e92d71552", "id": 3}, {"snippet_links": [{"key": "target-compound", "type": "definition", "offset": [10, 25]}], "size": 3, "samples": [{"hash": "9upL3uRqc6L", "uri": "/contracts/9upL3uRqc6L#candidate-compound", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "kW8XX4CQQ2M", "uri": "/contracts/kW8XX4CQQ2M#candidate-compound", "label": "Collaboration and License Agreement (Rib-X Pharmaceuticals, Inc.)", "score": 23.2806301117, "published": true}, {"hash": "lQs3XLRB1wW", "uri": "/contracts/lQs3XLRB1wW#candidate-compound", "label": "Collaboration and License Agreement (Rib-X Pharmaceuticals, Inc.)", "score": 22.9712524414, "published": true}], "snippet": "means any Target Compound that is nominated as a Candidate Compound under Section 2.7.", "hash": "8e9cca659a1a550bfbbc1b1829395abc", "id": 4}, {"snippet_links": [{"key": "research-and-development-committee", "type": "definition", "offset": [72, 106]}, {"key": "section-43", "type": "clause", "offset": [123, 134]}, {"key": "development-and-evaluation", "type": "clause", "offset": [154, 180]}, {"key": "this-agreement", "type": "clause", "offset": [187, 201]}], "size": 3, "samples": [{"hash": "8TdbGCZYN6r", "uri": "/contracts/8TdbGCZYN6r#candidate-compound", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "1Tf64n1GC8B", "uri": "/contracts/1Tf64n1GC8B#candidate-compound", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}], "snippet": "means a Recommended Compound which has been selected by the appropriate research and development committee of Sankyo under Section 4.3 hereof for further development and evaluation under this Agreement.", "hash": "d36bca74441cd22b5b09e76f9c4b7d32", "id": 5}, {"snippet_links": [{"key": "short-acting-coagulation-cascade-aptamer", "type": "definition", "offset": [27, 67]}, {"key": "in-the-course-of", "type": "definition", "offset": [99, 115]}, {"key": "this-agreement", "type": "clause", "offset": [135, 149]}, {"key": "pursuant-to", "type": "definition", "offset": [150, 161]}, {"key": "research-plan", "type": "definition", "offset": [174, 187]}], "size": 3, "samples": [{"hash": "dUOD6hY7zWv", "uri": "/contracts/dUOD6hY7zWv#candidate-compound", "label": "Collaboration and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}, {"hash": "8M3xNwpulhP", "uri": "/contracts/8M3xNwpulhP#candidate-compound", "label": "Collaboration and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}], "snippet": "means an Aptamer that is a Short Acting Coagulation Cascade Aptamer that is identified by Archemix in the course of its Research under this Agreement pursuant to an approved Research Plan.", "hash": "eb1ede118b46e32f1f0b53ac2f8d8168", "id": 6}, {"snippet_links": [{"key": "in-time", "type": "clause", "offset": [20, 27]}, {"key": "pfizer-compound", "type": "definition", "offset": [33, 48]}, {"key": "the-design", "type": "clause", "offset": [100, 110]}, {"key": "collaboration-plan", "type": "clause", "offset": [123, 141]}, {"key": "section-22", "type": "clause", "offset": [158, 169]}, {"key": "form-of", "type": "definition", "offset": [273, 280]}, {"key": "physical-form", "type": "definition", "offset": [351, 364]}], "size": 2, "samples": [{"hash": "jzJo1ZquxZZ", "uri": "/contracts/jzJo1ZquxZZ#candidate-compound", "label": "Research, Option and License Agreement (BIND Therapeutics, Inc)", "score": 24.6550312042, "published": true}, {"hash": "cO7dwUGNMaG", "uri": "/contracts/cO7dwUGNMaG#candidate-compound", "label": "Research, Option and License Agreement (BIND Therapeutics, Inc)", "score": 24.4880218506, "published": true}], "snippet": "means, at any point in time, any Pfizer Compound identified as a Candidate Compound at that time in the Design/Preclinical Collaboration Plan, as provided in Section 2.2, and any salt, stereoisomer, enantiomer, diastereomer, tautomer, racemate, free acid form or free base form of any such compound, including any hydrate, solvate, polymorph or other physical form of such compound.", "hash": "b2876a7ca6121a88e7068764226a7ee6", "id": 7}, {"snippet_links": [{"key": "primary-field", "type": "definition", "offset": [105, 118]}, {"key": "initial-screening", "type": "definition", "offset": [122, 139]}, {"key": "this-exhibit", "type": "definition", "offset": [163, 175]}, {"key": "request-for-confidential-treatment", "type": "clause", "offset": [207, 241]}, {"key": "the-commission", "type": "clause", "offset": [267, 281]}], "size": 2, "samples": [{"hash": "iGgdvqbPkOw", "uri": "/contracts/iGgdvqbPkOw#candidate-compound", "label": "Research and License Agreement (3 Dimensional Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "hme1gqDmhvb", "uri": "/contracts/hme1gqDmhvb#candidate-compound", "label": "Research and License Agreement (3 Dimensional Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means any Test Compound or Derivative ------------------ Compound which has demonstrated activity in the Primary Field in Initial Screening. **Certain portions of this Exhibit have been omitted based upon a request for confidential treatment that has been filed with the Commission. The omitted portions have been filed separately with the Commission.", "hash": "e098c78fc9809abfed7044ba01162c4f", "id": 8}, {"snippet_links": [{"key": "lead-molecule", "type": "definition", "offset": [8, 21]}, {"key": "basis-of", "type": "clause", "offset": [98, 106]}, {"key": "the-steering-committee", "type": "definition", "offset": [164, 186]}, {"key": "section-24", "type": "clause", "offset": [199, 210]}, {"key": "in-vitro-activity", "type": "definition", "offset": [231, 248]}, {"key": "for-development", "type": "clause", "offset": [272, 287]}, {"key": "in-vivo", "type": "definition", "offset": [304, 311]}, {"key": "the-exhibit", "type": "clause", "offset": [479, 490]}, {"key": "pursuant-to-a", "type": "definition", "offset": [508, 521]}, {"key": "request-for-confidential-treatment", "type": "clause", "offset": [522, 556]}, {"key": "under-rule", "type": "clause", "offset": [557, 567]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [579, 601]}, {"key": "as-amended", "type": "definition", "offset": [603, 613]}, {"key": "complete-exhibit", "type": "clause", "offset": [619, 635]}, {"key": "filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [722, 782]}, {"key": "intellectual-property-rights-of-third-parties", "type": "clause", "offset": [826, 871]}], "size": 2, "samples": [{"hash": "expfYMOtApU", "uri": "/contracts/expfYMOtApU#candidate-compound", "label": "Research Collaboration and License Agreement (Phytera Inc)", "score": 18.0, "published": true}, {"hash": "7mM2q2skJvv", "uri": "/contracts/7mM2q2skJvv#candidate-compound", "label": "Research Collaboration and License Agreement (Phytera Inc)", "score": 18.0, "published": true}], "snippet": "means a Lead Molecule or a compound ------------------ synthesized, identified or produced on the basis of a Lead Molecule that, in the reasonable determination of the Steering Committee pursuant to Section 2.4 (i), a) exhibits an in vitro activity and profile acceptable for Development, b) exhibits an in vivo activity and profile in a relevant animal model of disease acceptable for Development, c) is potentially patentable or otherwise ___________________ * This portion of the Exhibit has been omitted pursuant to a Request for Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended. The complete Exhibit, including the portions for which confidential treatment has been requested, has been filed separately with the Securities and Exchange Commission.\np.1 protectable and does not infringe the intellectual property rights of third parties, d) is one for which a plausible manufacturing strategy can be devised, and e) exhibits an acceptable therapeutic ratio in a 14-day toxicity model compared to the efficacy dose required in an animal model of disease.", "hash": "83d56c7fb503e08cfc523e5479b50984", "id": 9}, {"snippet_links": [{"key": "research-program", "type": "definition", "offset": [37, 53]}, {"key": "with-respect-to-an", "type": "clause", "offset": [89, 107]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [166, 195]}, {"key": "license-effective-date", "type": "definition", "offset": [314, 336]}, {"key": "licensed-compounds", "type": "definition", "offset": [401, 419]}, {"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [420, 454]}], "size": 1, "samples": [{"hash": "a3ppdBQdM8D", "uri": "/contracts/a3ppdBQdM8D#candidate-compound", "label": "Collaboration, Option and License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 36.8466803559, "published": true}], "snippet": "means, (a) with respect to the [***] Research Program, any Degrader that is [***] or (b) with respect to an Immunology Research Program, any Degrader that is: [***]. Notwithstanding the foregoing, all Candidate Compounds under a given Immunology Research Program will cease being Candidate Compounds following the License Effective Date for such Immunology Research Program whereupon they will become Licensed Compounds for the purposes of this Agreement. [***]", "hash": "ce7505b2ef81ec291a2ca311642b872e", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbY2FuZGlkYXRlLWNvbXBvdW5kIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 32, "title": "Candidate Compound", "snippet": "means:\n(a) any compound that has activity, with respect to the target protein expressed by the applicable Accepted Cell Line, which activity is initially discovered or detected by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line, where such activity is potentially useful for therapeutic or prophylactic use, or\n(b) any compound that is an analog, homolog, isomer or other chemical derivative of a compound that meets the criteria in subsection (a) above (the \u201cParent Compound\u201d), provided that such compound (i) was made by or on behalf of BMS or its Affiliate or sublicensee based on information relating to the Parent Compound, and (ii) has activity that is potentially useful for therapeutic or prophylactic use and is similar or related to the activity of such Parent Compound (with the understanding that such activity may be superior to the activity of the Parent Compound, in any appropriate criteria).", "id": "candidate-compound", "examples": ["BMS shall promptly notify Athersys of the first occurrence of any milestone with respect to each <strong>Candidate Compound</strong>.", "If BMS develops as a back-up <strong>Candidate Compound</strong> that inhibits or otherwise modulates the activity of a particular molecular target of a <strong>Candidate Compound</strong> on which BMS is already making milestone payments, then BMS may conduct clinical development on such back-up or follow-on <strong>Candidate Compounds</strong> and shall not be obligated to make any milestone payments with respect to any such back-up or follow-on <strong>Candidate Compound</strong>, except as otherwise provided below.", "Milestone payments shall be made only once with respect to any given <strong>Candidate Compound</strong>, regardless of the number of indications sought (or approvals obtained) with respect to such <strong>Candidate Compound</strong>, whether alone or in combination with other compounds or products, and regardless of any new dosage strengths, preparations or forms of administration for such <strong>Candidate Compound</strong>.", "For each Accepted Cell Line used in the Field, BMS shall pay Athersys the milestone payments set forth in Exhibit B within thirty (30) days after each milestone event has been achieved for each <strong>Candidate Compound</strong> identified for clinical development by BMS or its Affiliate or sublicensee for the particular Accepted Cell Line.", "In addition, for each <strong>Candidate Compound</strong> as to which Sanofi has exercised its Development and Commercialization Option under the preceding sentence, Sanofi will be entitled to designate two Back-up Compounds to such <strong>Candidate Compound</strong> to include as Licensed Compounds, such designation to be made by written notice given to Rib-X at any time during the Research Term or Follow-on Period.", "In addition, each Development Project Proposal for a <strong>Candidate Compound</strong> shall include an agreed upon Development Project Scope for which neither Party will have the ability to use any Collaboration IP to compete with such Development Project as defined in the corresponding Development Project Scope outside of the R&amp;D Collaboration.", "Screening Activities may include screening for and identifying (i) a Strain which produces the <strong>Candidate Compound</strong> or (ii) a Strain having a specific character or trait.", "If the Joint Steering Committee submits a Development Project Proposal for a <strong>Candidate Compound</strong> to the Management Committee and the Management Committee approves it, the <strong>Candidate Compound</strong> shall become a Lead Compound for development under a Development Project Plan (which Plan shall be the Development Project Proposal as adopted by the Management Committee).", "Any time after a <strong>Candidate Compound</strong> has been designated as a Development Compound, Nuvelo may determine that Development of such Development Compound should be abandoned.", "Nuvelo will have the sole right to designate a <strong>Candidate Compound</strong> as a Development Compound based on whether the <strong>Candidate Compound</strong> meets the relevant target product profile established by Nuvelo and set forth in the Research Plan or as subsequently modified by Nuvelo in good faith and communicated in writing to Archemix."], "related": [["lead-compound", "Lead Compound", "Lead Compound"], ["development-candidate", "Development Candidate", "Development Candidate"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["product-candidate", "Product Candidate", "Product Candidate"], ["licensed-compound", "Licensed Compound", "Licensed Compound"]], "related_snippets": [], "updated": "2025-11-08T04:50:29+00:00"}, "json": true, "cursor": ""}}